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Summary
• Hyperhomocysteinemia is an established risk factor for atheroscle-
rosis and vascular disease. Until the early nineties the relationship with
venous thrombosis was controversial. At this moment ten case-control
studies on venous thrombosis are published. We performed a meta-
analysis of these reports.
We performed a MEDLINE-search from 1984 through June 1997
on the keywords "homocysteine" or "hyperhomocysteinemia" and
"venous thrombosis", which yielded ten eligible case-control studies.
We found a pooled estimate of the odds ratio of 2.5 (95% CI 1.8-3.5)
for a fasting plasma homocysteine concentration above the 95th percen-
tile or mean plus two Standard deviations calculated from the distribu-
tion of the respective control groups. For the post-methionine increase
in homocysteine concentration we found a pooled estimate of 2.6
(95% CI1.6-4.4).
These data from case-control studies support hyperhomocystein-
emia äs a risk factor for venous thrombosis. Further research should
focus on the pathophysiology of this relationship and on the clinical
effects of reducing homocysteine levels by vitamin supplementation.
Introduction
Homocysteine is an amino acid, which was discovered in 1932 by
Vigneaud äs a product of transmethylation of methionine, an essential
amino acid (1). In the early sixties Carlson et al. äs well äs Gerritsen et
al. found very high levels of the disulphate homocystine in the urine
(homocystinuria) of some infants with mental retardation (2-4). In 1964
Mudd and colleagues reported the absence of cystathionine-ß-synthase
activity in the liver of a subject with homocystinuria (5). Because ho-
mocystinuria was found to be associated with vascular disease at young
age. it was supposed, that also the carrier state for homocystinuria
might be a risk factor for vascular disease. This carrier state was
thought to be identical with mildly elevated homocysteine levels, par-
ticularly after methionine loading. Up to now, more than thirty case-
control studies have been published which show an increased risk for
vascular disease due to hyperhomocysteinemia (6).
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Although Mudd reported äs early äs 1985 that 51% of the vascular
events in severe homocystinuria were of venous origin (7), the first
studies on the relation between mild hyperhomocysteinemia and
venous thrombosis were not published until 1991 (8,9). From 1991 to
now.in total eight case-control studies are published, which are subject
of the present review.
Methods
We performed a MEDLINE-search from 1984 through June 1998 on
the keywords "homocysteine" or "hyperhomocysteinemia" and "venous
thrombosis". We found a total of 117 articles of which 12 contain data from
case-control studies on venous thrombosis (8-19). Two papers reported the
same study (8,10). One study concerned only women using oral contraceptives
and reported only mean homocysteine concentrations (l 1). Therefore this study
was not included in the meta-analysis. Also the follow-up study of Kyrie et al.
was left out because this study concerned the risk of recurrent venous
thrombosis after a first event (20).
We derived the numbers of cases and control subjects with and without
hyperhomocysteinemia from the ten remaining studies. Hyperhomocystein-
emia was defined according to the reported study äs a plasma homocysteine con-
centration above the 95th percentile or mean plus 2 (or 2.7) times the Standard
deviation calculated from the distribution of the respective control groups (for
the study of Simioni only data about the 90th percentile were available). Be-
cause most studies with the methionine loading lest used post-methionine in-
crease in homocysteine concentration rather than absolute values we reanalysed
one study on recurrent venous thrombosis in terms of homocysteine increase
(13). We calculated (unmatched) odds ratlos for each of the studies with corre-
sponding confidence intervals. using Woolf's method.
A pooled estimate was calculated by a Mantel-Haenszel method. This meth-
od was used because two studies had no subjects with hyperhomocysteinemia
in their control group. So, for these studies no individual odds ratio could be
calculated. The confidence intervals of the Mantel-Haenszel estimates were
calculated by using the method of Robms (21). We also tested for homogeneity
äs reported by Greenland (22). This lest could only be applied to those studies
for which odds ratios can be calculated. Therefore we left out two studies with
no control subjects with hyperhomocysteinemia.
Results
Ten studies examined the relationship between hyperhomocystein-
emia and venous thrombosis (Table 1). The odds ratios for the fasting
state äs well äs after methionine loading are shown in Fig. 1.
In 1991 Bienvenu et al. (8,10) found elevated homocysteine levels
in a group of 17 patients with venous thrombosis compared to 49 con-
trol subjects. The same study was published in English language in
1993 with 23 patients and 49 control subjects. The patient group includ-
ed patients with rare presentations of venous thrombosis äs Budd-
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Fig. l A, B The odds ratios accordmg to elevated fastmg homocysteine levels (A) or elevated post-methionine homocysteine increase (B) in case-control studies
on venous thrombosis. Two studies (10, 12) are left out in the figure on fasting homocysteine levels because no odds ratios could be calculated
Chiari syndrome, central retinal vein occlusion and mesenterical
venous thrombosis.
Brattstrom et al. (9) reported no significant difference in mean plas-
ma homocysteine between patients with venous thrombosis and con-
trols in a small series of 42 patients and 42 controls. Interestingly, from
their data on post-methiomne increase a 3-fold elevated risk of hyper-
homocysteinemia for thrombosis could be calculated, which remained
non-significant likely due to the small sample size.
In 1994 Falcon et al. reported hyperhomocysteinemia äs a risk factor
for thrombosis occumng before the age of forty (12). They studied
patients with one or more episodes of venous thrombosis including
cerebral vein thrombosis (and excluding other thrombophilic disor-
ders), and healthy control subjects from the hospital staff. They report-
ed a difference in homocysteine level between cases and controls par-
ticularly after methionine loading. In 1995 we found hyperhomocys-
teinemia to be a risk factor for recurrent venous thrombosis in patients
between 20 and 70 years of age when compared to controls from the
general population (13).
Other studies, published in 1995 are the study of Amundsen et al.,
who found no significant difference in mean homocysteine in 35 pa-
tients (age less than 56) with deep-vein thrombosis and 39 controls (14)
and the study of Fermo et al. who found significantly higher prevalence
of hyperhomocysteinemia in 107 patients with venous thrombosis be-
fore the age of 45 compared with 60 healthy persons (15). They also
found an increased recurrence rate in patients with hyperhomocystein-
emia.
In 1996, we reported a population-based case-control study in pa-
tients with a first, objectively confirmed, episode of deep-vein throm-
bosis and control subjects of the general population (16). Another pop-
ulation-based study was published by Cattaneo et al. who studied 89 pa-
tients with a first episode of deep-vein thrombosis and 89 age and sex
matched controls (17). Both studies found an increased risk for venous
thrombosis due to hyperhomocysteinemia.
Simioni et al. published a study in 60 patients with proven DVT and
äs control subjects patients who were referred to the hospital because of
clinically suspected DVT but had normal venograms; they found an odds
Table l Characteristics of ten studies on
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ratio of 2.6 (18). Ridker et al. investigated homocysteine levels in the
Physicians' Health Study in 145 men who subsequently developed
venous thromboembolism and 646 men free of cardiovascular disease
(19). They concluded that hyperhomocysteinemia was associated with
idiopathic venous thrombosis but not with venous thrombosis of any
cause.
So, eight studies found hyperhomocysteinemia to be a risk factor for
venous thrombosis and two studies reported no relationship between
hyperhomocysteinemia and venous thrombosis. The other Fig. l shows
that all studies from which an odds ratio could be calculated, have point
estimates of the odds ratio above l .4. The pooled estimate for the fast-
ing homocysteine levels of all eight studies is 2.5 (95%CI 1.8-3.5). For
the post-methionine increase in homocysteine concentration we found a
pooled estimate of 2.6 (95% CI 1.6-4.4). The test for homogeneity -
which was restricted to those studies for which odds ratios could be cal-
culated - did not reach significance for either the fasting homocysteine
level (χ2 = 2.23, p >0.9, df = 7) äs well äs for the post-load homocys-
teine increase (χ2 = 3.36, p >0.5, df = 5); the distribution of the effect
measures over the studies, äs shown in Figs. 1A and 1B, also does not
point to heterogeneity of effect.
Discussion
The pooled estimates for fasting homocysteine and post-methionine
increase confirm the conclusion of most - except of two (9,14) - stud-
ies that hyperhomocysteinemia is a risk factor for venous thrombosis.
Notably, the odds ratios calculated for these two studies are very simi-
lar to the pooled estimate. The negative conclusions of these two stud-
ies are based on comparing mean homocysteine levels in patients and
control subjects and not on odds ratios äs estimates of risk.
Two studies are yet published which provide prospective data. The
study of Ridker et al. showed that subjects with increased homocysteine
levels are at increased risk for future venous thromboembolism (19).
Kyrie et al. reported that patients who already suffered from deep-vein
thrombosis had a higher risk for recurrences if they had elevated homo-
cysteine levels (20). These two studies strengthen the hypothesis that
homocysteine is causally associated with venous thrombosis.
The pooled estimates for both the fasting homocysteine level and the
post-methionine homocysteine increase are very similar. It is believed
that fasting homocysteine levels are more associated with remethyla-
tion defects while post-load increase of homocysteine are more asso-
ciated with transsulfuration defects. The similarity in odds ratios does
not point out whether venous thrombosis is more associated with re-
methylation defects or transsulfuration defects. The question whether
patients with venous thrombosis should underwent a methionine load-
ing test or that measurement of fasting homocysteine would be enough
could not be answered on the base of this meta-analysis because we
have no Information about the correlation between fasting homocys-
teine concentrations and post-load homocysteine increase.
Despite this epidemiological evidence for the relationship between
hyperhomocysteinemia and venous thrombosis, little is known about
its pathophysiology. A magnitude of possible mechanisms is proposed
with respect to vascular disease, which have been reviewed by several
authors (23-25). Many of these proposed mechanisms with respect to
arterial vascular disease may be applied to venous thrombosis äs well.
However, most hypotheses are based on in vitro experiments using very
high and unphysiological concentrations of homocysteine.
The clinical relevance of the fmding that hyperhomocysteinemia is a
risk factor for venous thrombosis depends mainly on its treatability by
vitamin supplementation. Especially folic acid has a strong homocys-
teine lowering effect (26-27). However, no data on clinical Intervention
studies are yet available and it cannot be ruled out that homocysteine is
an epiphenomen with respect to thrombosis, in which case vitamin
supplementation would probably be ineffective (28).
In conclusion, there is increasing evidence that mild hyperhomocys-
teinemia is a risk factor for venous thrombosis. Further research should
focus on the pathophysiology of thrombosis in hyperhomocysteinemia
and on the clinical effects of homocysteine lowering by means of vita-
min supplementation äs well äs on the interaction of this very common
abnormality with pther genetic or acquired thrombogenic defects.
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: iiaivtwii.Aî JO-Mn-zv;1;.·,?.;;:̂ ·:.̂ 1.::·..·'̂ .,:
$^&®$$&&$$'$\
Pinchera/Mann/Hostalek (Hrsg.)





Prevalence, clinical manifestations and therapeutic requirements of thyroid dis-
orders greafly differ during the course of life. There is a variety of diagnostic
and therapeutic problems in pregnant women which are relevant not only for
the endocrinologist, but also for the pediatrician and the gynecologist. The
development of the fetal thyroid and the pathogenesis of genetic diseases are
only partly understood. Screening for thyroid diseases in the newborn and
early treatment are offen inconsequentially performed.
In puberty, early diagnosis and prevention of thyroid diseases are of
tremendous socio-economical relevance, äs most goiters develop at this age.
In adults, iodine deficiency remains a world-wide risk that is responsible for
morbidity resulting from nodular goiter and thyroid autonomy. Iodine excess is
a common cause of iatrogenic thyroid disorders.
Thyroid diseases in the elderly are offen unrecognized and may substan-
tially contribute to morbidity and mortalily.
It is the aim of this book to focus fhe attention on age dependent aspects
of thyroid diseases and their specific diagnosis and treatment.
F. K. Schattauer Publishing Co. Stuttgart - New York
Distributors:
United States and Canada:
John Wiley & Sons, Inc., Wiley-Liss Division, 605 Third Avenue, New York, NY 101 58-0012/USA
UK, Eire, Spain, France, The Netherlands and South Africa:
Brilish Medical Journal, BMA House, Travistock Square, London WC1H 9JR
